In an article published in Life Science Leader's
January issue, Partner and Chair, Biotechnology & Life Sciences
Eric M. Brusca, Ph.D. discusses intellectual
property (IP) due diligence for life sciences companies. During a
due diligence project, sorting out a company’s IP portfolio
and freedom-to-operate status are the most time-consuming
parts.
“Initially, the parties involved in the potential
transaction must identify the relevant products, methods, or
services and establish whether the existing IP covers those
products or services,” Brusca explains. “Once a
comprehensive list of IP assets has been established, IP counsel
may begin digging deeper into the IP portfolio. Among the unique
considerations in the pharmaceutical and biotech world, the life
cycle of a product is often considered.”
